Several previous studies also revealed that the low activity of TLS including low expression of REV3L enhanced the chemosensitivity of cancer (Wang et al., 2015; Yang et al., 2015; Agulló-Ortuño et al., 2020), which supports our findings that patients in the DRG2 subtype may benefit from adjuvant chemotherapy. Here, REV3L is linked to cancer.